{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:28:54Z","timestamp":1775096934735,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41582-025-01138-y","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:03:46Z","timestamp":1758110626000},"page":"657-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A paradigm shift away from dissemination in time in multiple sclerosis"],"prefix":"10.1038","volume":"21","author":[{"given":"Agust\u00edn","family":"Pappolla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-5510","authenticated-orcid":false,"given":"Georgina","family":"Arrambide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"1138_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00270-4","author":"X Montalban","year":"2025","unstructured":"Montalban, X. et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4 (2025).","journal-title":"Lancet Neurol"},{"key":"1138_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/brain\/awy006","volume":"141","author":"G Arrambide","year":"2018","unstructured":"Arrambide, G. et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain 141, 1075\u20131084 (2018).","journal-title":"Brain"},{"key":"1138_CR3","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1212\/WNL.0000000000207664","volume":"101","author":"A Cobo-Calvo","year":"2023","unstructured":"Cobo-Calvo, A. et al. Association of very early treatment initiation with the risk of long-term disability in patients with a first demyelinating event. Neurology 101, e1280\u2013e1292 (2023).","journal-title":"Neurology"},{"key":"1138_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding, K. et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 76, 536\u2013541 (2019).","journal-title":"JAMA Neurol."},{"key":"1138_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1474-4422(23)00148-5","volume":"22","author":"AJ Solomon","year":"2023","unstructured":"Solomon, A. J. et al. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 22, 750\u2013768 (2023).","journal-title":"Lancet Neurol."},{"key":"1138_CR6","doi-asserted-by":"publisher","first-page":"100978","DOI":"10.1016\/j.lanepe.2024.100978","volume":"44","author":"MA Rocca","year":"2024","unstructured":"Rocca, M. A. et al. Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. Lancet Reg. Health Eur. 44, 100978 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1138_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210274","volume":"104","author":"WJ Brownlee","year":"2025","unstructured":"Brownlee, W. J. et al. Investigating whether dissemination in time is essential to diagnose relapsing multiple sclerosis. Neurology 104, e210274 (2025).","journal-title":"Neurology"},{"key":"1138_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1474-4422(17)30469-6","volume":"17","author":"M Filippi","year":"2018","unstructured":"Filippi, M. et al. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol. 17, 133\u2013142 (2018).","journal-title":"Lancet Neurol."},{"key":"1138_CR9","doi-asserted-by":"publisher","first-page":"e1641","DOI":"10.1212\/WNL.0000000000012726","volume":"97","author":"M Tintore","year":"2021","unstructured":"Tintore, M. et al. Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome. Neurology 97, e1641\u2013e1652 (2021).","journal-title":"Neurology"},{"key":"1138_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01138-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:03:27Z","timestamp":1764248607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01138-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01138-y","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"17 September 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.P has received travel funding from Roche and speaking honoraria from Novartis. G.A has received compensation for consulting services, speaking honoraria or participation in advisory boards from Bristol Myers Squibb, Horizon Therapeutics and Roche; has received travel support for scientific meetings from The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the European Academy of Neurology, Novartis and Roche; is a member of the International Women in Multiple Sclerosis network executive committee, the European Biomarkers in Multiple Sclerosis steering committee, the MOGAD Eugene Devic European Network steering group and the Platform Adaptive Trial for Remyelination and Neuroprotection in Multiple Sclerosis steering committee; and has participated in the steering team for the 2024 McDonald Diagnostic Criteria Preparatory Working Group by the International Advisory Committee on Clinical Trials in Multiple Sclerosis. X.M.\u2019s institution has received compensation for lecture honoraria and travel expenses, participation in scientific meetings, clinical trial steering committee membership, or clinical advisory board participation in recent years from Abbvie, Actelion, Alexion, Astrazeneca, Autolus, Bial PD, Biogen, Bristol-Myers Squibb\/Celgene, ECTRIMS, EMD Serono, Excemed, Genzyme, Hoffmann-La Roche, Immunic Therapeutics, Indivi, Janssen Pharmaceuticals, Juvis\u00e9 Pharmaceutical, Lilly, Medday, Medscape, Merck, Merz Therapeutics, the MS International Federation, Mylan-Viatris, the National MS Society, Nervgen, Neuraxpharm, Novartis, Peervoice, Rewind Therapeutics, Samsung-Biosys, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics and Zenas Biopharma or their affiliates.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}